A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 4, 2022

Primary Completion Date

December 28, 2022

Study Completion Date

December 28, 2022

Conditions
Healthy Subjects
Interventions
DRUG

Camizestrant

Subjects will be administered a single oral dose of Camizestrant on Day 1 of treatment period 1 and treatment period 3.

DRUG

Itraconazole

Subjects will be administered Itraconazole twice a day on Day 1 and once daily on Day 2 and Day 3 of treatment period 2, and once daily on Day 1, 2 and 3 of treatment period 3.

Trial Locations (1)

HA1 3UJ

Research Site, Harrow

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT05551897 - A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole | Biotech Hunter | Biotech Hunter